Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 May 26;8(2):E383-90.
doi: 10.1007/BF02854909.

Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse

Affiliations
Review

Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse

Eric Peterson et al. AAPS J. .

Abstract

Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with several candidates in preclinical and early clinical trials. Monoclonal antibodies can be designed that have customized affinity and specificity against drugs of abuse, and because antibodies can be designed in various forms, in vivo pharmacokinetic characteristics can be tailored to suit specific clinical applications (eg, long-acting for relapse prevention, or short-acting for overdose). Passive immunization with antibodies against drugs of abuse has several advantages over active immunization, but because large doses of monoclonal antibodies may be needed for each patient, efficient antibody production technology is essential. In this minireview we discuss some of the antibody forms that may be effective clinical treatments for drug abuse, as well as several current and emerging production systems that could bridge the gap from discovery to patient use.

PubMed Disclaimer

References

    1. Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration (Herrlisheim) 2002;69:193–197. doi: 10.1159/000063617. - DOI - PubMed
    1. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22:809–819. doi: 10.1016/S0192-0561(00)00042-4. - DOI - PubMed
    1. McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther. 1993;266:1439–1445. - PubMed
    1. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther. 1996;278:709–716. - PubMed
    1. Byrnes-Blake KA, Laurenzana EM, Carroll FI, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol. 2003;461:119–128. doi: 10.1016/S0014-2999(03)01313-X. - DOI - PubMed

Publication types

Substances